| Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and … MG Ghany, TR Morgan, AASLD‐IDSA hepatitis C guidance panel Hepatology 71 (2), 686-721, 2020 | 576 | 2020 |
| Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially … JR Morgan, BR Schackman, JA Leff, BP Linas, AY Walley Journal of substance abuse treatment 85, 90-96, 2018 | 368 | 2018 |
| Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection AIHCVG Panel Clinical infectious diseases: an official publication of the Infectious …, 2018 | 354 | 2018 |
| Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the United States EY Cramer, EL Ray, VK Lopez, J Bracher, A Brennen, ... Proceedings of the National Academy of Sciences 119 (15), e2113561119, 2022 | 339 | 2022 |
| Ensemble forecasts of coronavirus disease 2019 (COVID-19) in the US EL Ray, N Wattanachit, J Niemi, AH Kanji, K House, EY Cramer, J Bracher, ... MedRXiv, 2020.08. 19.20177493, 2020 | 244 | 2020 |
| Hepatitis C core antigen testing for diagnosis of hepatitis C virus infection: a systematic review and meta-analysis JM Freiman, TM Tran, SG Schumacher, LF White, S Ongarello, J Cohn, ... Annals of internal medicine 165 (5), 345-355, 2016 | 230 | 2016 |
| Priorities for screening and treatment of latent tuberculosis infection in the United States BP Linas, AY Wong, KA Freedberg, CR Horsburgh Jr American journal of respiratory and critical care medicine 184 (5), 590-601, 2011 | 221 | 2011 |
| Estimated prevalence of opioid use disorder in Massachusetts, 2011–2015: a capture–recapture analysis JA Barocas, LF White, J Wang, AY Walley, MR LaRochelle, D Bernson, ... American Journal of Public Health 108 (12), 1675-1681, 2018 | 192 | 2018 |
| Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort JR Morgan, BR Schackman, ZM Weinstein, AY Walley, BP Linas Drug and alcohol dependence 200, 34-39, 2019 | 172 | 2019 |
| Effect of fluvoxamine vs placebo on time to sustained recovery in outpatients with mild to moderate COVID-19: a randomized clinical trial MW McCarthy, S Naggie, DR Boulware, CJ Lindsell, TG Stewart, ... Jama 329 (4), 296-305, 2023 | 170* | 2023 |
| Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths JA Barocas, J Wang, BDL Marshall, MR LaRochelle, A Bettano, ... Drug and alcohol dependence 200, 59-63, 2019 | 158 | 2019 |
| The hepatitis C cascade of care: identifying priorities to improve clinical outcomes BP Linas, DM Barter, JA Leff, SA Assoumou, JA Salomon, MC Weinstein, ... PloS one 9 (5), e97317, 2014 | 155 | 2014 |
| The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through … SL Walsh, N El-Bassel, RD Jackson, JH Samet, M Aggarwal, AP Aldridge, ... Drug and alcohol dependence 217, 108335, 2020 | 151 | 2020 |
| Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC RP Walensky, A David Paltiel, E Losina, BL Morris, CA Scott, ER Rhode, ... Clinical infectious diseases 51 (4), 392-400, 2010 | 132 | 2010 |
| The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection BP Linas, DM Barter, JR Morgan, MT Pho, JA Leff, BR Schackman, ... Annals of internal medicine 162 (9), 619-629, 2015 | 124 | 2015 |
| A clash of epidemics: impact of the COVID-19 pandemic response on opioid overdose BP Linas, A Savinkina, C Barbosa, PP Mueller, M Cerdá, K Keyes, ... Journal of Substance Abuse Treatment 120, 108158, 2021 | 119 | 2021 |
| Association of treatment with medications for opioid use disorder with mortality after hospitalization for injection drug use–associated infective endocarditis SD Kimmel, AY Walley, Y Li, BP Linas, S Lodi, D Bernson, RD Weiss, ... JAMA network open 3 (10), e2016228-e2016228, 2020 | 109 | 2020 |
| A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial SS Solomon, S Wagner-Cardoso, L Smeaton, LA Sowah, C Wimbish, ... The Lancet Gastroenterology & Hepatology 7 (4), 307-317, 2022 | 108 | 2022 |
| Evaluation of individual and ensemble probabilistic forecasts of COVID-19 mortality in the US EY Cramer, EL Ray, VK Lopez, J Bracher, A Brennen, ... Medrxiv, 2021.02. 03.21250974, 2021 | 97 | 2021 |
| Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings SA Assoumou, A Tasillo, JA Leff, BR Schackman, ML Drainoni, ... Clinical Infectious Diseases 66 (3), 376-384, 2018 | 94 | 2018 |
